Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 01, 2022 08:47 ET | Source: Biofrontera Inc.

Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBCC with Ameluz®-PDT

WOBURN, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, is...
September 26, 2018 03:15 ET | Source: Biofrontera AG

Biofrontera starts patient recruitment for U.S. Phase III Trial Evaluating Ameluz® / BF-RhodoLED® for Superficial Basal Cell Carcinoma

Enrollment of 186 patients at 12 study sites in the U.S. startedPhase III trial completion for photodynamic therapy of superficial basal cell carcinoma expected in first half of 2020Filing for...